Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P51665
UPID:
PSMD7_HUMAN
Alternative names:
26S proteasome regulatory subunit RPN8; 26S proteasome regulatory subunit S12; Mov34 protein homolog; Proteasome subunit p40
Alternative UPACC:
P51665; D3DWS9; Q6PKI2; Q96E97
Background:
The 26S proteasome non-ATPase regulatory subunit 7, known by alternative names such as 26S proteasome regulatory subunit RPN8, S12, Mov34 protein homolog, and proteasome subunit p40, plays a crucial role in cellular function. It is a component of the 26S proteasome, a complex essential for the ATP-dependent degradation of ubiquitinated proteins, thereby maintaining protein homeostasis by removing misfolded or damaged proteins and those no longer needed.
Therapeutic significance:
Understanding the role of 26S proteasome non-ATPase regulatory subunit 7 could open doors to potential therapeutic strategies.